Clinical Trial Update: Atezolizumab + Guadecitabine in Patients With Checkpoint Inhibitor Refractory or Resistant Urothelial Carcinoma [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab plus guadecitabine in patients with checkpoint inhibitor refractory or resistant urothelial carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Atezolizumab (atezolizumab)
• Guadecitabine (guadecitabine)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Urothelial Carcinoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING